Sun Pharma Advanced Research Company · NSE: SPARC · BSE: 532872
Q2 FY23 results · Jul–Sep 2022
Sun Pharma Advanced Research Company reported revenue from operations of ₹31.54 crore (up 13.2% from Q2 FY22) and net loss of ₹68.40 crore for Q2 FY23 (Jul–Sep 2022), on a standalone basis.
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 31.54 | 27.87 | +13.2% | 28.46 | +10.8% |
| Other income | 0.06 | 5.98 | −99.0% | 0.18 | −66.7% |
| Total income | 31.60 | 33.85 | −6.6% | 28.64 | +10.3% |
| Profit before tax | (68.40) | (55.14) | Loss widened | (82.35) | Loss narrowed |
| Net profit for the period | (68.40) | (55.14) | Loss widened | (82.35) | Loss narrowed |
| EPS, basic (₹) | (2.52) | (2.09) | Loss widened | (3.03) | Loss narrowed |
| Net margin (%) | -216.9 | -197.8 | -289.4 |
Standalone
- Filed with BSE
- 09 Nov 2022, 10:31 IST
- Board meeting
- 07 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE